CARLSBAD, Calif.--(BUSINESS WIRE)--Applied Biosystems, part of Life Technologies Corporation (NASDAQ:LIFE), today announced the publication of a paper in the journal Nature that demonstrates the power of next-generation DNA sequencing used to identify DNA mutations in a small cell lung cancer (SCLC) line and identify the mutational burden associated with tobacco smoking. The paper, authored by researchers from the Wellcome Trust Cancer Institute and co-authored by Applied Biosystems, demonstrates the potential for next-generation sequencing to provide unprecedented insights into mutational processes, cellular repair pathways and gene networks associated with cancer development.
